High frequency of level II–V lymph node involvement in RET/PTC positive papillary thyroid carcinoma

2008 ◽  
Vol 34 (1) ◽  
pp. 77-81 ◽  
Author(s):  
Y.L. Wang ◽  
R.M. Zhang ◽  
Z.W. Luo ◽  
Y. Wu ◽  
X. Du ◽  
...  
Keyword(s):  
Lymph Node ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
High Frequency ◽  
Lymph Node Involvement ◽  
Papillary Thyroid ◽  
Level Ii ◽  
Node Involvement

scholarly journals Langerhans Cell Histiocytosis of the Thyroid with Multiple Cervical Lymph Node Involvement Accompanying Metastatic Thyroid Papillary Carcinoma

2014 ◽  
Vol 2014 ◽  
pp. 1-5
Author(s):  
A. Bahar Ceyran ◽  
Serkan Şenol ◽  
Barış Bayraktar ◽  
Şeyma Özkanlı ◽  
Z. Leyla Cinel ◽  
...  
Keyword(s):  
Lymph Node ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Langerhans Cell Histiocytosis ◽  
Cervical Lymph Node ◽  
Lymph Node Involvement ◽  
Langerhans Cell ◽  
Papillary Thyroid ◽  
Thyroid Papillary ◽  
Node Involvement

A 37-year-old male case was admitted with goiter. Ultrasonography of thyroid showed a 5 cm cystic nodule in the left lobe with a 1.5 cm solid component. Fine needle aspiration biopsy revealed atypia of undetermined significance or follicular lesion. The patient was operated on. The pathological diagnosis was reported as papillary thyroid carcinoma. The immunohistochemical examination showed multiple foci of Langerhans cell histiocytosis involving both lobes. The patient died due to cardiac arrest with respiratory causes in the early postoperative period. Langerhans cell histiocytosis is a rare primary condition which involves abnormal clonal proliferation of Langerhans cells in various tissues and organs. Thyroid involvement is infrequently seen. Although the etiology is unknown, genetic components may be linked to the disease. It is also associated with a family history of thyroid disease. Papillary thyroid carcinoma is the most common malignant epithelial tumor of the thyroid gland. Langerhans cell histiocytosis presenting with papillary thyroid carcinoma is rare. The privilege of our case is langerhans cell histiocytosis of the thyroid with multiple cervical lymph node involvement accompanying cervical lymph node metastatic thyroid papillary carcinoma.

scholarly journals Isthmusectomy for well-differentiated thyroid carcinoma located to the isthmus: A report of two cases and review of the literature

Medwave ◽  
2021 ◽  
Vol 21 (10) ◽  
pp. e8493-e8493
Author(s):  
Roberto Ignacio Olmos Borzone ◽  
Jorge Andrés López Ruiz-Esquide ◽  
Francisco Domínguez Covarrubias ◽  
José Miguel Domínguez Ruiz-Tagle
Keyword(s):  
Lymph Node ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Therapeutic Option ◽  
Lymph Node Involvement ◽  
Differentiated Thyroid Carcinoma ◽  
Papillary Thyroid ◽  
Node Involvement ◽  
Well Differentiated ◽  
Prophylactic Lymph Node Dissection

Papillary thyroid cancer is the most common endocrine malignancy, and due to its favorable prognosis, the extent of surgery has been a matter of debate. About 10% of these tumors are located in the thyroid isthmus, with no specific management in current guidelines. In the last decades, isthmusectomy has been proposed as a therapeutic option for isthmic papillary thyroid carcinoma, although there is no consensus on its management. We present two cases of patients from our institution with solitary isthmic papillary thyroid carcinoma without clinical macroscopic extrathyroidal extension or clinical-radiological lymph node involvement who were treated with isthmusectomy without prophylactic lymph node dissection. Neither of them had any postoperative complications. Both had an intermediate risk of recurrence due to aggressive variants. None of them had signs of recurrence during follow-up. We intend to show that isthmusectomy seems to be an effective and safe surgical alternative in selected patients through these cases.

Conservative surgical approach for thyroid and lymph-node involvement in papillary thyroid carcinoma of childhood and adolescence

2006 ◽  
Vol 46 (3) ◽  
pp. 307-313 ◽  
Author(s):  
Maura Massimino ◽  
Paola Collini ◽  
Silvia Fagundes Leite ◽  
Filippo Spreafico ◽  
Nicola Zucchini ◽  
...  
Keyword(s):  
Lymph Node ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Surgical Approach ◽  
Lymph Node Involvement ◽  
Childhood And Adolescence ◽  
Papillary Thyroid ◽  
Node Involvement

scholarly journals High Preponderance of BRAF V600E Mutation in Papillary Thyroid Carcinoma Among Filipinos: A Clinicopathologic Study

2019 ◽  
pp. 1-6
Author(s):  
Gerard Anthony M. Espiritu ◽  
Joemari T. Malana ◽  
Arlie Jean Grace V. Dumasis ◽  
Daphne C. Ang
Keyword(s):  
Lymph Node ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Braf Mutation ◽  
Lymph Node Involvement ◽  
Extrathyroidal Extension ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
Node Involvement

Purpose BRAF mutation in papillary thyroid carcinoma (PTC) is associated with an aggressive phenotype, with varying incidence. We evaluated the prevalence of BRAF mutations in PTC among Filipino patients and their correlation with clinicopathologic characteristics. Patients and Methods Clinicopathologic data were retrieved from 64 sequential patients who underwent thyroidectomy from June 2016 to December 2016. BRAF mutation testing was performed using Sanger sequencing. Results Eighteen (28%) of 64 patients were diagnosed with PTC; 12 (70.59%) of 17 harbored a BRAF V600E mutation (no amplification in one patient). Demographics of patients with PTC were as follows: 13 women and five men, with median age of 46 years (range, 25 to 74 years). Fourteen patients had conventional subtype PTC; two, follicular variant; one, oncocytic variant; and one, tall-cell features. Tumor size ranged from 0.8 to 7.0 cm (median, 2.4 cm); extrathyroidal extension was present in seven (38.9%) of 18 patients, multifocality in six (33.33%) of eight, and lymph node involvement in eight (44.4%) of 18. Significant association between presence of a BRAF mutation and presence of extrathyroidal extension or lymph node involvement was not determined due to the limited sample size. Conclusion The high preponderance of BRAF mutation (70.59%) suggests some correlation with the previously reported lower 5-year survival among Filipinos. This warrants further investigation in a larger-cohort prospective study.

Level I lymph node involvement in patients with N1b papillary thyroid carcinoma: a prospective study

2016 ◽  
Vol 274 (4) ◽  
pp. 1951-1958
Author(s):  
Ahmad M. Eweida ◽  
Mahmoud F. Sakr ◽  
Yasser Hamza ◽  
Mohamed R. Khalil ◽  
Essam Gabr ◽  
...  
Keyword(s):  
Lymph Node ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Prospective Study ◽  
Lymph Node Involvement ◽  
Papillary Thyroid ◽  
Node Involvement ◽  
Level I ◽  
A Prospective Study

scholarly journals Initial Presentation and Late Results of Treatment of Post-Chernobyl Papillary Thyroid Carcinoma in Children and Adolescents of Belarus

2014 ◽  
Vol 99 (8) ◽  
pp. 2932-2941 ◽  
Author(s):  
Mikhail Fridman ◽  
Natallia Savva ◽  
Olga Krasko ◽  
Svetlana Mankovskaya ◽  
Daniel I. Branovan ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lymph Node ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Children And Adolescents ◽  
Lymph Node Involvement ◽  
Papillary Thyroid ◽  
Free Survival ◽  
Node Involvement

Background: The aim of this population-based study was to evaluate the clinical and pathological characteristics and outcome of papillary thyroid carcinoma (PTC) that have arisen in the Belarusian childhood population exposed to the radioactive fallout from the Chernobyl accident within a long-term period. Patients and Methods: The long-term treatment results were investigated in 1078 children and adolescents (<19 years old) with PTC who were surgically treated during the years 1990 through 2005. Results: Patients had high rates of metastatic PTC at presentation, with 73.8% of cases having lymph node involvement and 11.1% having distant spread. The most influential factor for lymph node metastases at initial treatment was lymphatic vessel invasion (P < .0001) and for distant metastases, lateral lymph node involvement (P < .0001). The overall survival was 96.9% ± 0.9% with a median follow-up of 16.21 years, and 20-year event-free survival and relapse-free survival were 87.8% ± 1.6% and 92.3% ± 0.9%, respectively. Patients had significantly lower probability of both loco-regional (P < .001) and distant relapses (P = .005) after total thyroidectomy (TT) and radioactive iodine therapy (RAI). For loco-regional relapses after TT, only RAI influenced the prognosis significantly (P < .001). For distant relapses after TT, the refusal to treat with RAI (hazard ratio [HR] = 9.26), vascular invasion (HR = 8.68), and age at presentation (HR = 6.13) were significant risk factors. For loco-regional relapses after non-TT, the principal risk factors were age less than 15 years old at presentation (HR = 5.34) and multifocal growth of tumor (HR = 5.19). For distant relapses after non-TT, the lateral neck metastases were the only unfavorable factor (HR = 9.26). Conclusion: The outcome of PTC both in children and in adolescents exposed to the post-Chernobyl radioiodine fallout was rather favorable. TT with RAI is recommended for minimizing loco-regional or distant relapses.

Sign in / Sign up

Export Citation Format

Share Document